Aeglea BioTherapeutics
a lead clones are highly potent and characteristically diverse in preclinical studies an a | Aeglea BioTherapeutics
Deck date
October 2023
Slide
23 of 37
Related slides by other companies
Investor Presentation
February 2021
Other recent decks by Aeglea BioTherapeutics
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Mergers and Acquisitions
June 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io